Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A pioneering collaborative mouse study from an international team of researchers including Department of Physiology, Anatomy and Genetics Associate Professor Ana Domingos published in Nature offers new therapeutic avenues for reducing visceral fat stores, which have been associated with cardiovascular disease and multiple types of cancer.

Obesity has been linked to an increased risk of 13 types of cancer, including breast and colorectal, the two most prevalent cancers, together with cardiovascular disease, one of the leading causes of death worldwide. 

The most harmful type of obesity is caused by excessive accumulation of visceral fat, commonly called "deep" fat. While the most visible fat stores, or subcutaneous fat, are located directly under the skin, visceral fat is the fat stored inside our abdominal cavity, surrounding our vital internal organs. Normal amounts of visceral fat support a number of fundamental functions, such as reproduction. However, too much visceral fat produces unhealthy levels of proteins and hormones that negatively impact neighbouring tissues and organs, and it can be very difficult to eliminate.

DPAG’s Associate Professor Ana Domingos has collaborated with researchers from the Champalimaud Research Programme in Portugal and the Max Planck Institute for Metabolism Research in Germany to explore the mechanisms that naturally reduce visceral fat with the aim of uncovering potential clinical applications to benefit patients suffering from obesity. In doing so, they have uncovered the first known neuro-immune process by which brain signals instruct immune function in visceral fat stores. This discovery offers several new approaches to tackle obesity and its related illness.

Read the full story on the Department of Physiology, Anatomy and Genetics website

Similar stories

Population-scale study highlights ongoing risk of COVID-19 in some cancer patients despite vaccination

COVID-19 vaccination is effective in most cancer patients, but the level of protection against COVID-19 infection, hospitalisation and death offered by the vaccine is less than in the general population and vaccine effectiveness wanes more quickly.

New reporting guidelines developed to improve AI in healthcare settings

New reporting guidelines, jointly published in Nature Medicine and the BMJ by Oxford researchers, will ensure that early studies on using Artificial Intelligence (AI) to treat real patients will give researchers the information needed to develop AI systems safely and effectively.

Major boost for Oxford’s mission to counter future pandemic threats

The Moh Family Foundation has given a substantial gift to support the work of Oxford University’s Pandemic Sciences Institute, greatly strengthening its ability to identify and counter future pandemic threats and ensure equitable access to treatments and vaccines around the world.

Three NHSBT research units launch at University of Oxford

The NIHR has awarded three new Blood and Transplant Research Units (BTRUs) to the University of Oxford.

Fourth COVID-19 vaccine dose provides stronger immunity boost than third dose, shows UK study

COVID-19 vaccines given as fourth doses in the UK offer excellent boosting immunity protection, according to the latest results from a nationwide NIHR-supported study.